The radiopharmaceutical company NUCLIDIUM AG has raised an additional EUR 28.4 million in its Series B financing round. The company plans to use the capital to advance the clinical development of its copper-based radiotheranostics, expand global production capacity for diagnostics and therapeutics, and develop new targets for preclinical programs.
NUCLIDIUM, with sites in Basel and Munich, has announced the completion of an oversubscribed extension of its Series B financing round. With an additional CHF 26 million (approximately EUR 28.4 million), the total financing volume rises to CHF 105 million (approximately EUR 115 million).
The round was led by existing investors, including Kurma Growth Opportunities Fund, Angelini Ventures together with the EIB co-investment facility Aurea, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group). Other participants included DeepTech & Climate Fund (DTCF), Bayern Kapital, Vives Partners, and NRW.Bank.
NUCLIDIUM develops copper-based radiotheranostics that closely integrate the diagnosis and treatment of cancer. The company focuses on the isotopes copper-61 for diagnostic applications and copper-67 for therapeutic approaches. The two leading programs, NU101 for metastatic castration-resistant prostate cancer (mCRPC) and NU201 for metastatic breast cancer (mBC), are currently in clinical development.
NUCLIDIUM plans to use the additional funding to further develop its ongoing programs and initiate Phase 1/2a therapeutic trials for NU101 and NU201. In addition, the company plans to expand its international production and manufacturing network for diagnostics and therapeutics, as well as advance further preclinical programs for additional solid tumor indications.
"Emerging data from our Phase 1/2 diagnostics studies continue to generate strong momentum for NUCLIDIUM’S true radiotheranostics approach,“ said Dr. Leila Jaafar, CEO and co-founder of NUCLIDIUM. The financing validates the company’s strategy to further develop the next generation of copper-based radiotheranostics and realize the potential of this therapeutic approach.
Investors also see great potential in this field. Radiopharmaceuticals are currently among the most promising growth areas in oncology, explained Regina Hodits of Angelini Ventures, Daniel Parera of Kurma Partners, and Mario Costantini of Neva SGR on behalf of the participating investors. Particular emphasis was placed on the clinical superiority to competing radioligands and ease-of-use that supports seamless integration into hospital workflow.